The Phase III is of course the bread and butter so they don't want to generate any data that is going to be a thorn in their side later on. NBIX is on record saying that this Phase II for uterine fibroids would launch by the end of the 3rd quarter and the Phase III in endometriosis would launch in the 4th quarter. It has been slower than I would like, but I'm sure Abbott is crossing every single t and dotting every single i to make sure this is done correctly. Remember the indoplin disaster for NBIX....they have no power to push Abbott but probably wouldn't want to anyway. Indoplin was as close as you'll get to the finish line without crossing it. This is a huge shot on goal so I'm sure all involved just want everything done correctly. The big signal for me will be the launch of the Phase III. I think the markets agree with you that this has taken too long and it made investors nervous. However, so far things look on the track. As I said, the launch of the Phase III will make me much more relaxed.
S&P MAINTAINS BUY OPINION ON SHARES OF NEUROCRINE BIOSCIENCES (Standard & Poor's) NBIX's partner Abbott Labs (ABT 50.4, Buy) initiates Phase II study of elagolix for treatment of uterine fibroids, triggering a $10M milestone payment to NBIX. We are encouraged by the progress of the elagolix program, and continue to expect its advance to Phase III study in the more advanced indication of endometriosis before the end of '11. Although we see limited near-term share catalysts, we expect milestone payments to limit NBIX's cash burn enabling the funding of its earlier-stage clinical pipeline, led by Phase II VMAT2 inhibitor for movement disorder tardive dyskinesia.